ADL5747

· Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ADL5747, covering 2015-05-07 to 2015-07-08. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia [Phase 2]

See pricing